<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[velcade Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/velcade.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to velcade]]></description>
	<s:counts start="0" returned="20" found="39" />
	<language>en-us</language>
	<item>
		<title><![CDATA[FDA: Takeda Ad for Velcade Was Not Funny Enough]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002843/fda-takeda-ad-for-velcade-was-not-funny-enough/]]></link>
		<description><![CDATA[The FDA has warned Takeda's Millenium Pharma unit that utilizing a double entendre in a reminder ad is a violation of drug marketing law. The warning letter will be carefully noted by drug marketers their copywriting agencies and compliance departments as another restriction on their creativity. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 24 Jun 2009 10:59:31 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/compliance.html"><![CDATA[Compliance]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Takeda's Spree Peaks With Millennium Buy]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100013/takedas-spree-peaks-with-millennium-buy/]]></link>
		<description><![CDATA[The Japanese are coming!    Well, to be exact, one Japanese drugmaker, Takeda Pharmaceutical,  is coming. And the big question is whether its recent buying spree -- capped by its $8.8 billion acquisition of the biotech Millennium Pharmaceuticals announced today -- will leave it looking more like...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 11 Apr 2008 12:53:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/takeda.html"><![CDATA[Takeda]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[The International Myeloma Foundation Says Newly Diagnosed Patients Could Benefit from FDA "Priority Review" of VELCADEŽ for Front-Line Use]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_4/ai_n24245186]]></link>
		<description><![CDATA[NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation IMF - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said the FDA decision granting "priority review" for VELCADE[R] in newly diagnosed myeloma recognizes the benefits of powerful new therapies and the need...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 04 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/benefit.html"><![CDATA[benefit]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Gemin X's Pan-Bcl-2 Antagonist GX15-070 Permits Rational Combination with Velcade in Mantle Cell Lymphoma]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_13/ai_n27083783]]></link>
		<description><![CDATA[Data Presented in an Oral Presentation at American Society of Hematology Annual Meeting]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 13 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/ibm+corp..html"><![CDATA[IBM Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">IBM</category>
		<category domain="tickers">IBM</category>
	</item>
	<item>
		<title><![CDATA[EmergingMarketsllc.com: Emerging Equity Alerts.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200606/ai_n19557198]]></link>
		<description><![CDATA[M2 PRESSWIRE-16 June 2006-Emerging Markets Consulting, LLC.:  EmergingMarketsllc.com: Emerging Equity AlertsC1994-2006 M2  COMMUNICATIONS LTD    RDATE:16062006    Orlando, FL - Stocks gaining traction in yesterday's trading  are Millennium Pharmaceuticals, Inc., (NASDAQ: MLNM), Encysive  Pharmaceuticals, Inc., (NASDAQ: ENCY), Discovery Laboratories, Inc.,  (NASDAQ:...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 16 Jun 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/commercialization.html"><![CDATA[commercialization]]></category>
		<category domain="http://resources.bnet.com/topic/equity.html"><![CDATA[equity]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">MLNM,NDAQ</category>
	</item>
	<item>
		<title><![CDATA["Stocks on the Rise".]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200506/ai_n19880683]]></link>
		<description><![CDATA[M2 PRESSWIRE-15 June 2005-WallStreetGrapevine: "Stocks on the  Rise"C1994-2005 M2 COMMUNICATIONS LTD    RDATE:15062005    Wall Street, NYC - Today, wallstreetgrapevine.com, named; FacePrint  Global Solutions, Inc. (OTC BB: FCPG), Aastrom Biosciences, Inc. (Nasdaq  SC: ASTM), Millennium Pharmaceuticals, Inc. (Nasdaq NM: MLNM), and  Abgenix...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 15 Jun 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/aastrom+biosciences+inc..html"><![CDATA[Aastrom Biosciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/abgenix+inc..html"><![CDATA[Abgenix Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/authentication%252fencryption.html"><![CDATA[Authentication/Encryption]]></category>
		<category domain="http://resources.bnet.com/topic/conference.html"><![CDATA[conference]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[stock]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ASTM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">ASTM,MLNM,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[FDA Approves Millenium's VELCADE -bortezomib- for Use in Second-Line Multiple Myeloma; International Myeloma Foundation Applauds Approval of New Therapy]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_March_29/ai_n13480450]]></link>
		<description><![CDATA[NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation IMF, the country's oldest and largest myeloma organization, applauds the U.S. Food and Drug Administration's FDA approval of VELCADER. This approval expands the label to include the treatment of multiple myeloma patients who have received at least one prior therapy. The approval...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 29 Mar 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Zacks.com Announces That Nadine Wong Highlights the Following Stock: Millenium Pharmaceuticals]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_Sept_28/ai_n6216937]]></link>
		<description><![CDATA[CHICAGO -- Nadine Wong is raising sales and earnings estimates for one cancer company, and explains why she expects 2005 to turn to profitability with upside from a massive pipeline. Read about Millenium Pharmaceuticals (NASDAQ:MLNM). Nadine Wong is editor of the Biotech Stock Report newsletter. Click here for the full...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 28 Sep 2004 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/millennium.html"><![CDATA[Millennium]]></category>
		<category domain="http://resources.bnet.com/topic/newsletter.html"><![CDATA[newsletter]]></category>
		<category domain="http://resources.bnet.com/topic/nhl.html"><![CDATA[NHL]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[stock]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[VELCADE (Bortezomib) for Injection Data Show a Significant Improvement in Survival in Patients With Relapsed Multiple Myeloma]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111462]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. discusses the results from its phase III confirmatory APEX trial which show a statistically significant improvement in survival in patients treated in the VELCADE alone arm compared to those treated with high-dose dexamethasone. These data include an approximate 30 percent reduction in the risk...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Sat, 05 Jun 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[Millennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patients With Indolent Non-Hodgkin's Lymphoma]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111466]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE Bortezomib for injection in combination with rituximab in patients with relapsed or refractory indolent follicular and marginal zone non-Hodgkin's lymphoma. The randomized study will assess efficacy, overall safety and tolerability of the...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Thu, 13 May 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[Millennium acquires rights to proteasome inhibitors and related synthesis techonology - agreement to augment company's proteasome inhibitor program-.(Millennium Pharmaceuticals Inc.)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6487/is_200405/ai_n25821574]]></link>
		<description><![CDATA[Millennium Pharmaceuticals, Inc. (Cambridge, MA) today announced it  has signed a research agreement with Harvard University and Professor  E.J. Corey for a family of proteasome inhibitors and a related chemical  synthesis process. Millennium intends to utilize the agreement to  enhance the Company's ongoing efforts to develop...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sat, 01 May 2004 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/harvard+university.html"><![CDATA[Harvard University]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[VELCADE (Bortezomib) for Injection: Prescribing Information]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111406]]></link>
		<description><![CDATA[This article focuses and gives details on prescribing VELCADE which is indicated for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates. The trials of VELCADE include...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Wed, 14 Apr 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
	</item>
	<item>
		<title><![CDATA[Cambridge, Mass.-Based Pharmaceutical Firm Expects Big Sales for Cancer Drug.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5553/is_200401/ai_n22096698]]></link>
		<description><![CDATA[By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business  News    Jan. 13--Millennium Pharmaceuticals Inc. yesterday said it expects  to  sell up to $160 million worth of its Velcade cancer drug this year,  nearly  three times its 2003 sales, and said layoffs and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 13 Jan 2004 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/boston+globe.html"><![CDATA[Boston Globe]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[Millennium Announces Assignment of Medicare Code for Velcade (Bortezomib) for Injection]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111436]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. informs that the Center for Medicare and Medicaid Services CMS has qualified VELCADE for pass-through status and assigned it to a Healthcare Common Procedure Coding System HCPCS whereby hospitals may obtain reimbursement for VELCADE under the hospital outpatient prospective payment system OPPS effective October...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Fri, 26 Sep 2003 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/medicare.html"><![CDATA[Medicare]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[Millennium overhauls operations. (Markets: Life Sciences).(Millennium Pharmaceuticals Inc)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200306/ai_n13211484]]></link>
		<description><![CDATA[MILLENNIUM Pharmaceuticals Inc. will trim its global work force by  26 percent and consolidate operations under a restructuring plan for  profitability by 2006. The move comes on the heels of a critical Food  and Drug Administration FDA approval for    MILLENNIUM Pharmaceuticals Inc. will trim...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 16 Jun 2003 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/life+science.html"><![CDATA[life science]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE (Bortezomib) for Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=112298]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. discusses the results of several clinical trials with its novel oncology product VELCADE, in which early signs of anti-tumor activity were observed with VELCADE as both a single agent and in combination with other therapies. VELCADE Studied as a Single Agent in Non-Hodgkin's Lymphoma...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 02 Jun 2003 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[VELCADE (Bortezomib) for Injection]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111444]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. informs about the approval from the U.S. Food and Drug Administration FDA to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Thu, 15 May 2003 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[FDA Accepts for Review NDA Filing and Grants Priority Review for Velcade (Bortezomib) for Injection]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111431]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. reveals that the U.S. Food and Drug Administration FDA accepted for review and granted Priority Review designation of the Company's New Drug Application NDA for VELCADE for the treatment of relapsed and refractory multiple myeloma. Priority Review is granted by the FDA to an...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 10 Mar 2003 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/priority+review.html"><![CDATA[Priority Review]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE) 3.5MG Powder for Solution for Injection]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111430]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a complete Marketing Authorization Application MAA to the European Agency for the Evaluation of Medicinal Products EMEA for the approval of bortezomib VELCADE as a treatment for relapsed and refractory multiple myeloma. This application was submitted approximately one week...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 04 Feb 2003 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
	<item>
		<title><![CDATA[Millennium Submits New Drug Application for VELCADE (Bortezomib) for Injection]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=111429]]></link>
		<description><![CDATA[In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a New Drug Application NDA with the U.S. Food and Drug Administration FDA for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma. In June 2002, VELCADE was granted fast-track status by the FDA as...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Wed, 22 Jan 2003 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/velcade.html"><![CDATA[VELCADE]]></category>
		<category domain="http://resources.bnet.com/topic/millennium+pharmaceuticals+inc..html"><![CDATA[Millennium Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MLNM</category>
		<category domain="tickers">MLNM</category>
	</item>
</channel>
</rss>
